CIFoundry
Back to Catalog
Cardiology
FDA Cleared
Pathway Labs / Columbia University Irving Medical Center / NewYork-Presbyterian2026

Last reviewed Nov 11, 2026 against the sources listed on this page · How we review

At a glance

EchoNext is an AI tool that analyzes standard 12-lead ECGs to flag hidden structural heart disease, including left- and right-sided heart failure, valve disease, severe hypertrophy consistent with…

FDA:
510(k) K260332
Epic:
Not on record
Named users:
2 reported by the maker
Published study:
Yes, linked below

Description

EchoNext is an AI tool that analyzes standard 12-lead ECGs to flag hidden structural heart disease, including left- and right-sided heart failure, valve disease, severe hypertrophy consistent with infiltrative cardiomyopathy and pulmonary hypertension, so patients can be referred for an echocardiogram. It was developed at NewYork-Presbyterian and Columbia and is commercialized by Pathway Labs; clinicians can access it through OpenEvidence. FDA 510(k) K260332, cleared June 8, 2026.

ECGstructural heart diseasedeep learningscreeningFDA-clearedheart failurevalve disease

Quick answers

Answered only from the sourced records on this page. Questions we can't answer from the record are left out. How we review

Is EchoNext FDA cleared?
The public FDA database has one record that our team matched to EchoNext. The most recent is 510(k) K260332 (EchoNext), decided Jun 2026. Check that the cleared use matches how you plan to use it.FDA record K260332
Is there published research on EchoNext?
Yes, this listing links a published study. Check whether the patients and setting in the study look like yours.Some authors of this study work for or have financial ties to the maker.Read the study

Security & contracting

The maker has not reported these details yet. Ask the vendor directly during evaluation.

Workflow stage
Not reported
Integrations
Not reported
Data inputs
Not reported
Deployment
Not reported
Signs a BAA
Not reported
SOC 2 report
Not reported
HITRUST
Not reported
Evidence type
Not assessed
Study authors
Include people who work for or have financial ties to the maker

Readiness details are self-reported by the maker and are not checked by Clinical Intelligence Foundry. Evidence type describes the kind of study or document the listing links to; it is not a rating or endorsement. Confirm compliance documents with the vendor before purchase.

Who's using this

2 organizations

Organizations named in public announcements or by the developer. Inclusion is not an endorsement.

Reported by the developer

NewYork-PresbyterianColumbia University Irving Medical Center

Last checked Oct 31, 2026. Spot an error? Let us know through the discussion below.

Get weekly updates for Cardiology

Up to 5 new items a week: new tools, FDA decisions and studies. Newest first, never ranked. Confirm by email, unsubscribe any time.

Sources

This listing links to primary sources. Follow the links below to check details directly with the developer, regulator or publication.

Website Research Paper

Some authors of this study work for or have financial ties to the maker.

FDA database records

  • K260332 · 510(k) · Jun 2026
    EchoNext

Matched by our team from the public FDA database; checked Nov 10, 2026.

History (2)Show

Dated events on this listing's public record, newest first.

  1. Sep 13, 2026

    Added to CIFoundry

  2. Jun 8, 2026

    FDA 510(k) K260332 decision datesource

Developer

Pathway Labs (Pathwai, Inc.)

Pathway Labs / Columbia University Irving Medical Center / NewYork-Presbyterian

Evaluating this tool?

Get a printable packet for your committee: what the public record shows, the gaps to raise with the vendor, and the questions for this kind of tool.

Prepare evaluation packet

Checklist for your role: Admin · Physician · IT · Compliance

Compare similar tools →

Own this tool?

Claim this listing to update its details and connect with your audience.